12:10 PM EDT, 07/21/2025 (MT Newswires) -- ZimVie ( ZIMV ) shares surged intraday Monday after the dental implant company agreed to be acquired and taken private by healthcare-focused investment firm Archimed for about $730 million.

Shareholders of ZimVie ( ZIMV ) will receive $19 per share in cash, almost double the company's 90-day average price, it said. The transaction is not subject to a financing condition.

The company's stock soared 122% in midday trading.

The deal, which requires clearance from regulators and ZimVie's ( ZIMV ) shareholders, is expected to close by the end of this year. Its stock will no longer trade publicly after deal completion.

"This transaction marks a new chapter for ZimVie ( ZIMV )," Chief Executive Vafa Jamali said in a statement. "Partnering with Archimed will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally."

The deal includes a "go-shop" period of 40 days, allowing the company to solicit alternative acquisition proposals.

In May, ZimVie ( ZIMV ) reported first-quarter adjusted earnings of $0.27 per share, up from $0.08 the year before. Sales declined 5.2% to $112 million. At the time, the company said it expected adjusted EPS in a range of $0.80 to $0.95 for the full year, with sales coming in between $445 million and $460 million.

"We're excited to partner with ZimVie ( ZIMV ) and its talented team," Archimed's managing partner, Andre-Michel Ballester, said in the Monday statement. "The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter."

Price: 18.76, Change: +10.32, Percent Change: +122.22